Nettet24. apr. 2024 · S-531011是Shionogi开发的新型抗人 IgG1 抗体，在肿瘤浸润Tregs中选择性表达，对表达CCR8的细胞具有体外抗体依赖性细胞毒性，并对CCL1-CCR8信号通路具有中和活性。动物和体外实验显示，小鼠静脉注射S-531011 可显着减少肿瘤浸润性 CCR8+ Tregs，并显着抑制肿瘤生长。 Nettet2024年12月27日，吉利德科学公司和Jounce Therapeutics, Inc.修订了GS-1811（原JTX-1811）的现有许可协议，使吉利德能够买断在2024年8月执行的许可协议下可能到期的剩余或有付款。作为交易的一部分，双方在许可协议中规定的与GS-1811（一种抗CCR8抗体）有关的某些运营义务 ...
Our Pipeline Jounce Therapeutics
Nettet2. nov. 2024 · CAMBRIDGE, Mass., Nov. 02, 2024 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the … Nettet15. jun. 2024 · Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody Read full article ... lvf to pdf
Jounce Therapeutics, Inc. (JNCE) - Stock Analysis
Nettet2. nov. 2024 · Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable … Nettet22. jun. 2024 · We are excited to share the first results from our anti-CCR8 program, demonstrating JTX-1811’s ability to deplete immunosuppressive tumor infiltrating T regs and to provide synergistic activity with PD-1 inhibitors in otherwise PD-1 inhibitor resistant tumor models,” said Elizabeth Trehu, M.D., chief medical officer of Jounce Therapeutics. Nettet15. aug. 2024 · JTX-1811, recently developed by Jounce Therapeutics (Cambridge, MA, USA) in collaboration with Gilead (Foster City, CA, USA), is a humanized mAb with enhanced ADCC activity to selectively deplete ... lv fs 13c 47db a++ blanc brandt - dwf137dw